Sandro Pignata

Medicine & Life Sciences

1. Ovarian Neoplasms 100%
2. Platinum 40%
3. Drug Therapy 35%
4. Carboplatin 27%
5. Bevacizumab 27%
6. Progression-Free Survival 27%
7. Multicenter Studies 25%
8. Neoplasms 22%
9. Survival 20%
10. Ovarian Epithelial Carcinoma 19%
11. Therapeutics 19%
12. Paclitaxel 18%
13. Carcinoma 18%
14. Renal Cell Carcinoma 17%
15. olaparib 16%
16. Nivolumab 15%
17. Endometrial Neoplasms 13%
18. Poly(ADP-ribose) Polymerase Inhibitors 13%
19. Trabectedin 12%
20. Immunotherapy 12%
21. liposomal doxorubicin 12%
22. Medical Oncology 11%
23. Retrospective Studies 11%
24. Safety 10%
25. Italy 9%
26. Human Influenza 9%
27. Kidney Neoplasms 8%
28. Uterine Cervical Neoplasms 8%
29. Granulosa cell tumor of the ovary 8%
30. Recurrence 8%
31. Cytoreduction Surgical Procedures 8%
32. Amine Oxidase (Copper-Containing) 8%
33. Germ Cell and Embryonal Neoplasms 7%
34. Biomarkers 7%
35. pazopanib 7%
36. Radiotherapy 6%
37. Placebos 6%
38. Observational Studies 6%
39. Hepatocellular Carcinoma 6%
40. Maintenance 6%
41. Clinical Trials 6%
42. Elderly 6%
43. Guidelines 5%
44. Coronavirus 5%
45. Prospective Studies 5%
46. Confidence Intervals 5%
47. Oncologists 5%
48. Disease Progression 5%
49. Influenza Vaccines 5%
50. niraparib 5%